Edition:
India

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

3.54USD
2:29am IST
Change (% chg)

$-0.11 (-3.01%)
Prev Close
$3.65
Open
$3.79
Day's High
$3.79
Day's Low
$3.53
Volume
29,115
Avg. Vol
33,393
52-wk High
$5.11
52-wk Low
$1.90

Latest Key Developments (Source: Significant Developments)

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article

Fortress Biotech posts Q3 loss per share $0.67
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Fortress Biotech Inc :Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.67.Q3 revenue $46.9 million versus $1.0 million.  Full Article

Fortress Biotech announces pricing of series a preferred stock offering
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Fortress Biotech Inc :Fortress Biotech Inc announces pricing of series a preferred stock offering.Fortress Biotech Inc - ‍priced offering of one million shares of its 9.375 pct series a cumulative redeemable perpetual preferred stock at $25.00 per share​.  Full Article

Fortress Biotech proposes public offering of Series A preferred stock
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Fortress Biotech Inc :Fortress Biotech announces proposed public offering of Series A preferred stock.  Full Article

Mustang Bio enters lease agreement for production of Car T therapies
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Fortress Biotech Inc :Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​.Facility is expected to be operational for production of personalized Car T therapies in 2018​.Has entered into a lease agreement with UMASS Medicine Science Park in Worcester, Massachusetts​.  Full Article

Mustang Bio announces $12.8 mln grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Fortress Biotech Inc ::Mustang Bio announces $12.8 million grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma.  Full Article

Fortress Biotech Q4 revenue $16.5 mln
Friday, 17 Mar 2017 

Fortress Biotech Inc : Fortress Biotech reports financial results for the fourth quarter and full year ended december 31, 2016 .Q4 revenue $16.5 million.  Full Article

Fortress Biotech files for mixed shelf of up to $53 mln
Friday, 19 Aug 2016 

Fortress Biotech Inc :Files for mixed shelf of up to $53 million - SEC filing.  Full Article

Fortress Biotech says entered amended and restated at market issuance sales agreement
Thursday, 18 Aug 2016 

Fortress Biotech : Pursuant to agreement co may issue and sell shares having offering price of up to $70 million from time to time through mlv and FBR .On aug 17, 2016, entered into amended and restated at market issuance sales agreement, or sales agreement - sec filing.  Full Article

BRIEF-Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial

* MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL